Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.36B P/E - EPS this Y -44.00% Ern Qtrly Grth -
Income -188.86M Forward P/E -8.38 EPS next Y 27.80% 50D Avg Chg -
Sales 863.49M PEG -0.30 EPS past 5Y - 200D Avg Chg 16.00%
Dividend N/A Price/Book 0.88 EPS next 5Y 12.00% 52W High Chg -36.00%
Recommedations 1.50 Quick Ratio 1.13 Shares Outstanding 696.99M 52W Low Chg 76.00%
Insider Own 52.41% ROA -4.73% Shares Float 331.18M Beta 1.84
Inst Own 25.34% ROE -12.80% Shares Shorted/Prior 78.03M/102.16M Price 1.76
Gross Margin 26.47% Profit Margin -21.87% Avg. Volume 3,801,127 Target Price 4.25
Oper. Margin -37.97% Earnings Date Aug 1 Volume 2,222,674 Change -3.30%
About Opko Health, Inc.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Opko Health, Inc. News
10:47 AM OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
05:56 AM Q1 2024 OPKO Health Inc Earnings Call
02:44 AM OPKO Health Inc (OPK) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves Amid ...
05/07/24 Opko Health (OPK) Q1 2024 Earnings Call Transcript
05/07/24 OPKO Health (OPK) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
05/07/24 OPKO Health Inc (OPK) Q1 2024 Earnings: Misses Revenue and Earnings Estimates
05/07/24 OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates
05/07/24 OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results
05/03/24 OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
04/01/24 OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
04/01/24 Labcorp (LH) to Boost Clinical Diagnostics With New Deal
03/28/24 Labcorp inks $237.5M buyout of Opko’s reproductive, women’s health testing assets
03/28/24 Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
03/25/24 OPKO Health (OPK) And Entera Bio Announce Data for GLP-2
03/20/24 Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
03/05/24 AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV
03/01/24 Analysts Have Lowered Expectations For OPKO Health, Inc. (NASDAQ:OPK) After Its Latest Results
02/29/24 OPKO Health, Inc. (NASDAQ:OPK) Q4 2023 Earnings Call Transcript
02/29/24 OPKO Health Full Year 2023 Earnings: EPS Beats Expectations
02/28/24 NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st
OPK Chatroom

User Image ViractaTrader77 Posted - 1 hour ago

$OPK Massive ADC initiation.

User Image tradertrash Posted - 2 hours ago

$OPK there a wet dream mgt for Shorts OVERSPENDING i'm not a CPA, but any idiot could see there debits severely exceed there credits

User Image Mike18181 Posted - 3 hours ago

$OPK Opko health announces it will Buy Teldar paper and merge there managerial synergies together. Both companies are lossing money, mismagement in both, direction. To celebrate the merger both companies will have a pool party full of vomit, Large Cow crap, and dung. They will do the back stroke in this pool and enjoy there performance. Both CEOs agree we can useca Giant Tird as a Floatation device. Opko shares up +.01

User Image Mike18181 Posted - 3 hours ago

$OPK Q2 revenue will reflect another drop of -25,000,000 million. So revenue would be 150 to 155m Losses will be what ? They will revisit $ 1.00 or lower. Its on them and message board people arent opko executives. Opko executives are not qualified to produce profits.

User Image Cooco Posted - 4 hours ago

$OPK 2024 doesnt really look good on for us. Only if our OPK management really cares and doing really well. Who goes to earning reports with a bad background noise.. you can they they dont care lol

User Image Mike18181 Posted - 4 hours ago

$OPK Fact : Insolvency is when a companies cashflow will no longer cover expenses and generate ongoing losses. Selling off assets, reseting notes is an indication of a drowning company. Carnival cruises reset notes several time as they are at full capacity and still trying to stay afloat. There losses got better. Opko losses are half of there revenue. CCL guys good job to this point. ! It was very rough seas ... """Opko created there own rough seas as they wont change or budget..""

User Image littleal01 Posted - 4 hours ago

$OPK Bag Holder Since 2015... 22K Shares... I See A Full Spectrum of Highly Paid Execs and Board Members... Yet, Nothing But A Straight Line Declining Share Price With Absolutely No Explanation To Shareholders... I Mean NOTHING... Does Anyone Know What's Happening Here and/or The Endgame For This Company? It's On Par With DJT!!!

User Image Mike18181 Posted - 4 hours ago

$OPK Average down in Opko stock is what Fixaleg wrote. You will end up with a larger pile of Dung. But you have more dung now.

User Image Mike18181 Posted - 4 hours ago

$OPK Cogratulations to the entire Opko team for reaching another Milestone ! The ability to post pone Delisting.. We worked hard to deliver shareholders a return on Equity. Our results are Clear ! Yes, real clear.. And most of the investment houses that recommended your stock to clients are in a Psychiatric Hospital.

User Image Fixaleg Posted - 5 hours ago

$OPK this steaming pile of crap remains the biggest Jewel of the Bile ever found in the stock market! Consistent performance for the last 5-10yrs to the downside with never ending list of disappointments thanks to a really piss poor exec team and defunct product lines! Scam really -

User Image AdiDasRom Posted - 5 hours ago

$OPK OPKO Health Inc (NASDAQ:OPK) announced a significant asset sale to LabCorp, expected to streamline operations and enhance profitability in the diagnostics segment. The company's long-acting growth hormone therapy is gaining traction globally, with Pfizer expanding its launch in over 40 markets, indicating strong commercial progress. OPKO Health Inc (NASDAQ:OPK) has several promising pharmaceutical programs set to enter clinical trials, including a multi-specific oncology antibody and a vaccine licensed to Merck. The company has secured non-dilutive funding through collaborations, including a $59 million grant from Barda for COVID-19 related research, supporting financial stability. OPKO Health Inc (NASDAQ:OPK) is making strides in precision oncology with its GenPath performance and expanded testing platforms, showing over 12% growth in volume.

User Image Mike18181 Posted - 5 hours ago

$OPK " Put more wood in the fire to keep it going " ! Lets sell off something else . Sell off executive suite, giant tropical fish tank in the lobby, catering contracts, suspend quaterly cruises, stop Jon Cohen executive ongoing severence package, ski lodge membership, Sell off the Opko building and move to modex HQ. Cash raised 100.million, now were good for 2 more quartes as the stock rallies !!

User Image G101SPM Posted - 6 hours ago

$OPK $1.16 bid. DAC (dollar average cost) (2) $1.275 last $1.01 (1.18.24). CHANGE EXIT TO $6.50 FROM $8.15. UPDATE: Reports Q1 (Mar) loss of $(0.12) per share, $0.02 worse than the FactSet Consensus of ($0.10); revenues $173.7 mln vs the $182.99 mln consensus.

User Image Rain9991 Posted - 6 hours ago

$OPK At this point, the deal has already been made, they are just in the process of restructuring it according to the buyers wishes. Again, you don’t buy 250 million shares to fix the company, you are selling g it…he’s 88

User Image steviem Posted - 17 hours ago

$OPK Frost will get his due in the afterlife.

User Image Mike18181 Posted - 17 hours ago

$OPK 173.000.00 Q1 revenue and a - 81.000.000 ------------------------------------- = Piss poor management

User Image High_RollN Posted - 18 hours ago

$OPK Why doesn’t management just come out and apologize for letting all the investors down for the last 10 years?? I think this would make some people feel a little better about their failures and mishaps!!!

User Image Cooco Posted - 19 hours ago

$OPK management cant really do shiet for the SH! Unfortunately !

User Image Cooco Posted - 19 hours ago

$OPK this will be down 10-20 more % tomorrow

User Image Cooco Posted - 19 hours ago

$OPK shorts are about to pull something again tomorrow.

User Image Cooco Posted - 20 hours ago

$OPK managements are really bad.

User Image Cooco Posted - 20 hours ago

$OPK this will go back to below $1

User Image tymtested Posted - 20 hours ago

$OPK Ngenla sales clearly disappointing

User Image ItsAllAboutBeingFirst Posted - 20 hours ago

$OPK couldn’t tell u the last time w had a green day post earnings this

User Image Mike18181 Posted - 20 hours ago

$OPK I am day trading my savings account as its more active than Opko. Revenues continue to decline, and more good news released said the Monkey !

User Image Meltingflame Posted - 20 hours ago

$OPK Not the result I hoped for, but I am holding all my shares. Average at $1.01/share. When the dust settles will add more. 20k shares at the moment. Bullish!!

User Image lecorb Posted - 20 hours ago

$OPK OPKO Health GAAP EPS of -$0.12 misses by $0.02, revenue of $173.7M misses by $9.29M

User Image Tomic5 Posted - 20 hours ago

$OPK Frost will buy more, I will wait for 1.10 range

User Image epsguid Posted - 20 hours ago

$OPK reported a loss of $0.12, consensus was ($0.09) via @eWhispers #epsmiss http://eps.sh/d/opk

User Image Mactoast Posted - 20 hours ago

$OPK Quick read, looks like shit again. Carry on!

Analyst Ratings
HC Wainwright & Co. Buy Apr 3, 24
Barrington Research Outperform Apr 1, 24
Piper Sandler Overweight Apr 1, 24
HC Wainwright & Co. Buy Feb 28, 24
Barrington Research Outperform Feb 28, 24
HC Wainwright & Co. Buy Aug 7, 23
Barrington Research Outperform Jun 29, 23
HC Wainwright & Co. Buy May 5, 23
HC Wainwright & Co. Buy Mar 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
KRASNO RICHARD M Director Director Jan 29 Buy 0.9946 30,000 29,838 103,333 01/29/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 19 Buy 0.9773 500,000 488,650 205,868,225 01/19/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 18 Buy 0.9655 400,000 386,200 205,368,225 01/18/24
HSIAO JANE PH D Vice Chairman & CTO Vice Chairman & CTO Jan 17 Buy 0.95 150,000 142,500 27,999,880 01/17/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 16 Buy 0.9543 1,000,000 954,300 204,968,225 01/16/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 11 Buy 0.9391 511,531 480,379 203,968,225 01/11/24
Nabel Gary J. Chief Innovation Off.. Chief Innovation Officer Jan 08 Buy 0.92 216,184 198,889 107,489 01/10/24
HSIAO JANE PH D Vice Chairman & CTO Vice Chairman & CTO Jan 04 Buy 0.8726 150,010 130,899 27,849,880 01/08/24
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jan 04 Buy 0.8964 1,500,000 1,344,600 203,456,694 01/08/24
Zerhouni Elias A. Vice Chairman and Pr.. Vice Chairman and President Jan 05 Buy 0.91 550,300 500,773 20,327,814 01/05/24
PFENNIGER RICHARD C JR Director Director Jan 05 Buy 0.94 25,000 23,500 325,000 01/05/24
Rubin Steven D Executive VP-Adminis.. Executive VP-Administration Nov 10 Buy 1.30 10,000 13,000 6,177,732 11/13/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 17 Buy 1.76 100,000 176,000 200,956,694 08/18/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 14 Buy 1.75 75,000 131,250 200,856,694 08/15/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 09 Buy 1.82 100,000 182,000 200,781,694 08/10/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 07 Buy 1.84 650,000 1,196,000 200,681,694 08/08/23
Nabel Gary J. Chief Innovation Off.. Chief Innovation Officer May 05 Buy 1.82 460,245 837,646 242,747 05/08/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Mar 22 Buy 1.32 200,000 264,000 200,031,694 03/23/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Mar 08 Buy 1.2 1,000,000 1,200,000 199,831,694 03/09/23
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Nov 22 Buy 1.49 300,000 447,000 198,831,694 11/23/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Nov 09 Buy 1.6 200,000 320,000 198,531,694 11/10/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Oct 27 Buy 1.82 100,000 182,000 198,331,694 10/28/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Oct 19 Buy 1.71 100,000 171,000 198,231,694 10/20/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 26 Buy 1.8 50,000 90,000 197,756,694 09/27/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 23 Buy 1.85 50,000 92,500 197,706,694 09/26/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 22 Buy 1.9 50,000 95,000 197,656,694 09/23/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 21 Buy 1.91 50,000 95,500 197,606,694 09/22/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 20 Buy 1.94 50,000 97,000 197,556,694 09/21/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 19 Buy 1.97 50,000 98,500 197,506,694 09/20/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Sep 02 Buy 2.14 100,000 214,000 197,256,694 09/06/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 17 Buy 2.54 200,000 508,000 197,156,694 08/18/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Aug 05 Buy 2.28 350,000 798,000 196,956,694 08/08/22
Nabel Gary J. Chief Innovation Off.. Chief Innovation Officer Jun 22 Buy 2.49 240,000 597,600 80,000 06/24/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 21 Buy 2.4 200,000 480,000 196,606,694 06/22/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 16 Buy 2.32 100,000 232,000 196,406,694 06/17/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 13 Buy 2.36 100,000 236,000 196,306,694 06/14/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 06 Buy 2.8 100,000 280,000 196,206,694 06/07/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Jun 01 Buy 2.97 50,000 148,500 196,106,694 06/02/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 31 Buy 3.03 50,000 151,500 196,056,694 06/01/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 25 Buy 2.98 50,000 149,000 196,006,694 05/26/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 18 Buy 2.88 50,000 144,000 195,956,694 05/19/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 16 Buy 2.98 150,000 447,000 195,906,694 05/17/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 13 Buy 3 200,000 600,000 195,756,694 05/16/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 11 Buy 2.831 400,000 1,132,400 195,556,694 05/12/22
Zerhouni Elias A. Vice Chairman and Pr.. Vice Chairman and President May 09 Buy 2.7946 89,600 250,396 89,600 05/11/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman May 10 Buy 2.7839 400,000 1,113,560 195,156,694 05/11/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Mar 14 Buy 3.04 35,000 106,400 194,756,694 03/15/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Mar 11 Buy 3.13 100,000 313,000 194,721,694 03/14/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Feb 28 Buy 3.1 100,000 310,000 194,621,694 03/01/22
FROST PHILLIP MD ET AL CEO & Chairman CEO & Chairman Feb 25 Buy 3.0871 750,000 2,315,325 194,521,694 02/28/22